Your browser doesn't support javascript.
loading
Long-Term Outcome of Lobectomy for Thyroid Cancer.
Bosset, Matthieu; Bonjour, Maxime; Castellnou, Solène; Hafdi-Nejjari, Zakia; Bournaud-Salinas, Claire; Decaussin-Petrucci, Myriam; Lifante, Jean Christophe; Perrin, Agnès; Peix, Jean-Louis; Moulin, Philippe; Sassolas, Geneviève; Pugeat, Michel; Borson-Chazot, Françoise.
Affiliation
  • Bosset M; Fédération d'Endocrinologie, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France.
  • Bonjour M; Service de Biostatistique, Hospices Civils de Lyon, Lyon, France.
  • Castellnou S; Fédération d'Endocrinologie, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France.
  • Hafdi-Nejjari Z; Registre des Cancers Thyroïdiens du Département du Rhône, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France.
  • Bournaud-Salinas C; Centre de Médecine Nucléaire, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France.
  • Decaussin-Petrucci M; Service d'Anatomie-Pathologique, Hospices Civils de Lyon, Groupement Hospitalier Lyon-Sud, Pierre Bénite, France.
  • Lifante JC; Service de Chirurgie Endocrinienne, Hospices Civils de Lyon, Groupement Hospitalier Lyon-Sud, Pierre Bénite, France.
  • Perrin A; Laboratoire Health Services and Performance Research (EA 7425 HESPER), Université Claude Bernard Lyon 1, Villeurbanne, France.
  • Peix JL; Fédération d'Endocrinologie, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France.
  • Moulin P; Service de Chirurgie Endocrinienne, Hospices Civils de Lyon, Groupement Hospitalier Lyon-Sud, Pierre Bénite, France.
  • Sassolas G; Fédération d'Endocrinologie, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France.
  • Pugeat M; CarMeN Laboratory, Université Claude-Bernard Lyon 1, Inserm U1060, INRA U1397, INSA Lyon, IMBL, Villeurbanne, France.
  • Borson-Chazot F; Registre des Cancers Thyroïdiens du Département du Rhône, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France.
Eur Thyroid J ; 10(6): 486-494, 2021 Nov.
Article in En | MEDLINE | ID: mdl-34956920
ABSTRACT

INTRODUCTION:

Recent guidelines of the American Thyroid Association (ATA) suggest that a lobectomy may be sufficient to treat low- to intermediate-risk patients with thyroid tumors ≤40 mm, without extrathyroidal extension or lymph node metastases. The present study aimed to evaluate long-term recurrence after lobectomy for differentiated thyroid cancer and to analyze factors associated with recurrence.

METHODS:

In this retrospective cohort study, patients who underwent a lobectomy for thyroid cancer in a tertiary center between 1970 and 2010 were included. The outcome was the proportion of pathology-confirmed thyroid cancer recurrence, assessed in the whole cohort or in subgroups according to tumor size (≤ or >40 mm).

RESULTS:

A total of 295 patients were included, and these were followed-up for a mean (standard deviation, SD) 19.1 (7.8) years (5,649 patient-years); 61 (20.7%) were male and the mean (SD) age at diagnosis was 39.7 (12) years. Histological subtype was papillary in 263 (89.2%) patients and mean cancer size was 22.9 (16.9) mm. According to the 2015 ATA guidelines, 271 (91.9%) cancers had a low risk of recurrence and 24 (8.1%) an intermediate risk. A reoperation was performed in 54 patients (18.3%) and recurrence was confirmed in 40 (13.6%), diagnosed for 55% of cases more than 10 years after their initial surgery. Among recurrent patients, 14 (4.8% of the cohort) were operated for a contralateral papillary thyroid microcarcinoma and 26 (8.8% of the cohort) for a locoregional or metastatic recurrence. Non-suspicious nodular recurrences were monitored without reoperation in 53 (18.0%) patients. At the end of follow-up, 282 (95.6%) patients were in remission. Tumors with locoregional or metastatic recurrence were more frequent among tumors with aggressive histology (19.2 vs. 4.1%, p = 0.015) and of intermediate risk category (28.6 vs. 7.1%, p = 0.018). Tumors >40 mm, which would have been treated by thyroidectomy according to the 2015 ATA guidelines criteria, were found in 34 (11.5%) patients and were associated with a higher frequency of recurrence (20.6 vs. 7.3%, p = 0.024) and less remission (85.3 vs. 96.9%, p = 0.001).

CONCLUSION:

The outcome of thyroid cancer treated by lobectomy is very good, particularly for cancer ≤40 mm. A prolonged follow-up is required due to the risk of late recurrence.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline / Observational_studies / Risk_factors_studies Language: En Journal: Eur Thyroid J Year: 2021 Type: Article Affiliation country: France

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline / Observational_studies / Risk_factors_studies Language: En Journal: Eur Thyroid J Year: 2021 Type: Article Affiliation country: France